Trial · NCT04597190
Sequenced Treatment Effectiveness for Posttraumatic Stress
NCT04597190, Phase 4, Completed, University of Washington; results first posted 2025-03-26
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Sequenced Treatment Effectiveness for Posttraumatic Stress. Trials, record NCT04597190. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04597190
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Sequenced Treatment Effectiveness for Posttraumatic Stress
- NCT number
- NCT04597190
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 700 participants, actual
- Lead sponsor
- University of Washington
- Conditions
- PTSD
- Interventions
- Selective serotonin reuptake inhibitor, Serotonin-norepinephrine reuptake inhibitor, Written Exposure Therapy
- First posted
- 2020-10-22
- Last updated
- 2025-05-08
- Results first posted
- 2025-03-26
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | PTSD Symptoms | 4 months (Hypothesis 1) | Self reported burden of PTSD symptoms (PCL-5) (range 0-80, higher scores are worse) |
| Primary | PTSD Symptoms | 8 Months (Hypotheses 2a and 2b) | Self reported burden of PTSD symptoms (PCL-5) (range 0-80, higher scores are worse) |
| Secondary | Mental Health Related Quality of Life: SF-12V, Mental Health Component Summary Score | 4 months (Hypothesis 1) | SF-12V, Mental Health Component Summary Score (range 0-100, higher scores are better) |
| Secondary | Mental Health Related Quality of Life: SF-12V, Mental Health Component Summary Score | 8 Months (Hypotheses 2a and 2b) | SF-12V, Mental Health Component Summary Score (range 0-100, higher scores are better) |
| Secondary | Depression Symptoms | 4 months (Hypothesis 1) | Self reported burden of depression symptoms (PHQ-9) (range 0-27, higher scores are worse) |
| Secondary | Depression Symptoms | 8 Months (Hypotheses 2a and 2b) | Self reported burden of depression symptoms (PHQ-9) (range 0-27, higher scores are worse) |
| Secondary | Generalized Anxiety Symptoms | 4 months (Hypothesis 1) | Self reported burden of anxiety symptoms (GAD-7) (range 0-21, higher scores are worse) |
| Secondary | Generalized Anxiety Symptoms | 8 Months (Hypotheses 2a and 2b) | Self reported burden of anxiety symptoms (GAD-7) (range 0-21, higher scores are worse) |
| Other | Number of Severe and Moderate Side Effects | 4 months (Hypothesis 1) | Self reported severity of specific side-effects |
| Other | Number of Severe and Moderate Side Effects | 8 Months (Hypotheses 2a and 2b) | Self reported severity of specific side-effects |
Source ClinicalTrials.gov
Outcomes10
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | PTSD Symptoms | 4 months (Hypothesis 1) | units on a scale | MEAN | |
| PRIMARY | PTSD Symptoms | 8 Months (Hypotheses 2a and 2b) | Participants not responding to treatment at 4-months who completed the 8-month survey | units on a scale | MEAN |
| SECONDARY | Mental Health Related Quality of Life: SF-12V, Mental Health Component Summary Score | 4 months (Hypothesis 1) | units on a scale | MEAN | |
| SECONDARY | Mental Health Related Quality of Life: SF-12V, Mental Health Component Summary Score | 8 Months (Hypotheses 2a and 2b) | Participants not responding to treatment at 4-months who completed the 8-month survey | units on a scale | MEAN |
| SECONDARY | Depression Symptoms | 4 months (Hypothesis 1) | Participants completing the 4-month survey | units on a scale | MEAN |
| SECONDARY | Depression Symptoms | 8 Months (Hypotheses 2a and 2b) | Participants not responding to treatment at 4-months who completed the 8-month survey | units on a scale | MEAN |
| SECONDARY | Generalized Anxiety Symptoms | 4 months (Hypothesis 1) | Participants completing the survey at 4-months | units on a scale | MEAN |
| SECONDARY | Generalized Anxiety Symptoms | 8 Months (Hypotheses 2a and 2b) | Participants not responding to treatment at 4-months who completed the 8-month survey | units on a scale | MEAN |
| OTHER_PRE_SPECIFIED | Number of Severe and Moderate Side Effects | 4 months (Hypothesis 1) | Participants completing the 4-month survey | Number of side-effects | MEAN |
| OTHER_PRE_SPECIFIED | Number of Severe and Moderate Side Effects | 8 Months (Hypotheses 2a and 2b) | Participants not responding to treatment at 4-months who completed the 8-month survey | Number of side-effects | MEAN |
Source ClinicalTrials.gov
Results by group30
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| PTSD Symptoms | SSRI Then Augmentation by WET | 39.3 | Standard Deviation 17.8 | units on a scale | |
| PTSD Symptoms | SSRI Then Switch to SNRI | 38.6 | Standard Deviation 17.0 | units on a scale | |
| PTSD Symptoms | WET Then Switch to SSRI | 40.5 | Standard Deviation 18.4 | units on a scale | |
| PTSD Symptoms | SSRI Then Augmentation by WET | 49.3 | Standard Deviation 17.0 | units on a scale | |
| PTSD Symptoms | SSRI Then Switch to SNRI | 42.1 | Standard Deviation 17.2 | units on a scale | |
| PTSD Symptoms | WET Then Switch to SSRI | 44.5 | Standard Deviation 17.3 | units on a scale | |
| Mental Health Related Quality of Life: SF-12V, Mental Health Component Summary Score | SSRI Then Augmentation by WET | 34.7 | Standard Deviation 11.6 | units on a scale | |
| Mental Health Related Quality of Life: SF-12V, Mental Health Component Summary Score | SSRI Then Switch to SNRI | 34.1 | Standard Deviation 12.2 | units on a scale | |
| Mental Health Related Quality of Life: SF-12V, Mental Health Component Summary Score | WET Then Switch to SSRI | 32.9 | Standard Deviation 11.0 | units on a scale | |
| Mental Health Related Quality of Life: SF-12V, Mental Health Component Summary Score | SSRI Then Augmentation by WET | 29.4 | Standard Deviation 12.3 | units on a scale |
1 to 10 of 30Source ClinicalTrials.gov
See all 30 results by groupParticipant flow9
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | SSRI Then Augmentation by WET | 169 | |
| Overall Study | STARTED | SSRI Then Switch to SNRI | 179 | |
| Overall Study | STARTED | WET Then Switch to SSRI | 352 | |
| Overall Study | COMPLETED | SSRI Then Augmentation by WET | 145 | |
| Overall Study | COMPLETED | SSRI Then Switch to SNRI | 150 | |
| Overall Study | COMPLETED | WET Then Switch to SSRI | 295 | |
| Overall Study | NOT COMPLETED | SSRI Then Augmentation by WET | 24 | |
| Overall Study | NOT COMPLETED | SSRI Then Switch to SNRI | 29 | |
| Overall Study | NOT COMPLETED | WET Then Switch to SSRI | 57 |
Source ClinicalTrials.gov
Adverse events18
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Increase in suicide ideation | Investigations | SSRI Then Augmentation by WET | 33 | 169 | 33 |
| other | Increase in suicide ideation | Investigations | SSRI Then Switch to SNRI | 35 | 179 | 35 |
| other | Increase in suicide ideation | Investigations | WET Then Switch to SSRI | 60 | 352 | 60 |
| other | Non-suicidal injury | Investigations | SSRI Then Augmentation by WET | 1 | 169 | 1 |
| other | Non-suicidal injury | Investigations | SSRI Then Switch to SNRI | 0 | 179 | 0 |
| other | Non-suicidal injury | Investigations | WET Then Switch to SSRI | 0 | 352 | 0 |
| serious | Hospitalization | Investigations | SSRI Then Augmentation by WET | 1 | 169 | 1 |
| serious | Hospitalization | Investigations | SSRI Then Switch to SNRI | 3 | 179 | 3 |
| serious | Hospitalization | Investigations | WET Then Switch to SSRI | 7 | 352 | 7 |
| serious | Emergency Department Admission | Investigations | SSRI Then Augmentation by WET | 0 | 169 | 0 |
1 to 10 of 18Source ClinicalTrials.gov
See all 18 adverse eventsAdverse event totals9
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | SSRI Then Augmentation by WET | 0 | 169 |
| Total, all-cause mortality | SSRI Then Switch to SNRI | 0 | 179 |
| Total, all-cause mortality | WET Then Switch to SSRI | 1 | 352 |
| Total, other adverse events | SSRI Then Augmentation by WET | 34 | 169 |
| Total, other adverse events | SSRI Then Switch to SNRI | 35 | 179 |
| Total, other adverse events | WET Then Switch to SSRI | 60 | 352 |
| Total, serious adverse events | SSRI Then Augmentation by WET | 32 | 169 |
| Total, serious adverse events | SSRI Then Switch to SNRI | 34 | 179 |
| Total, serious adverse events | WET Then Switch to SSRI | 63 | 352 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 41091477 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04597190
GET https://conductscience.org/api/trials/v1/NCT04597190/results?page=2